(+)-VINCRISTINE
Lymphoma, Low-grade
Eisai Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Lymphoma, Low-grade cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Eisai Inc. | Phase 2 | B |
Inno-206 Eisai Inc. | Phase 2 | B |
Denileukin Diftitox Eisai Inc. | Phase 2 | CCC |
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →